001037886 001__ 1037886
001037886 005__ 20250203103255.0
001037886 037__ $$aFZJ-2025-01029
001037886 1001_ $$0P:(DE-Juel1)131691$$aKroll, Tina$$b0$$eCorresponding author$$ufzj
001037886 1112_ $$a62. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin$$cLeipzig$$d2024-04-10 - 2024-04-13$$wGermany
001037886 245__ $$aAwake PET with the adenosine A1 receptor radiotracer F-18-CPFPX in rats: Optimization of reference region and route of injection
001037886 260__ $$c2024
001037886 3367_ $$033$$2EndNote$$aConference Paper
001037886 3367_ $$2BibTeX$$aINPROCEEDINGS
001037886 3367_ $$2DRIVER$$aconferenceObject
001037886 3367_ $$2ORCID$$aCONFERENCE_POSTER
001037886 3367_ $$2DataCite$$aOutput Types/Conference Poster
001037886 3367_ $$0PUB:(DE-HGF)24$$2PUB:(DE-HGF)$$aPoster$$bposter$$mposter$$s1738052487_29914$$xAfter Call
001037886 520__ $$aFor the adenosine A1 receptor tracer F-18-CPFPX the olfactory bulb is an established reference region in rats. However, quantitative awake PET with radioactive point sources attached to the animal’s head for motion correction might be biased by spill-in from the nasal point source to the olfactory bulb. Moreover, for imaging without any anesthesia, intravenous (i.v.) injection of the tracer is demanding and stressful for the animal. This study investigates the feasibility of the pons as reference region and intraperitoneal (i.p.) tracer injection for quantitative analysis of F-18-CPFPX PET in awake rats. Eight male rats underwent six dynamic PET scans each following either an i.v. or i.p. bolus of F-18-CPFPX. For both conditions, two subsequent scans were performed under awake condition followed by a scan under anesthesia. The outcome parameter BPND determined via the simplified reference-tissue model (reference: olfactory bulb or pons) was evaluated in terms of variability and reproducibility. In-vitro H-3-DPCPX saturation autoradiography of the same animals served for validation of in-vivo outcome parameters.In-vitro Bmax and F-18-CPFPX BPNDpons correlated significantly (all p<0.01) for i.v. (r=0.81-0.86) and i.p. (r=0.81-0.88) injection route for awake and anesthetized condition. Test-retest stability of BPNDpons after i.p. tracer injection performed best when comparing the different conditions and gave reliable results in awake animals with high test-retest correlations (r=0.99, p<0.01) and an acceptable absolute variability (mean over all regions 15.3±5.8%).Quantitative awake small-animal PET imaging with F-18-CPFPX is improved by applying a reference region with lower probability of radioactive spill-in from point sources and practicability can be enhanced by i.p. tracer injection without loss of quantitative accuracy.
001037886 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001037886 536__ $$0G:(EU-Grant)680966$$aNEURON Cofund - ERA NET NEURON in the area of brain-related diseases and disorders of the nervous system (680966)$$c680966$$fH2020-HCO-2015$$x1
001037886 7001_ $$0P:(DE-HGF)0$$aMiranda, Alan$$b1
001037886 7001_ $$0P:(DE-Juel1)159581$$aDrechsel, Alexandra$$b2$$ufzj
001037886 7001_ $$0P:(DE-Juel1)151362$$aKlein, Sabina$$b3$$ufzj
001037886 7001_ $$0P:(DE-Juel1)133864$$aBeer, Simone$$b4$$ufzj
001037886 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b5$$ufzj
001037886 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b6$$ufzj
001037886 7001_ $$0P:(DE-HGF)0$$aVerhaeghe, Jeroen$$b7
001037886 7001_ $$0P:(DE-Juel1)131679$$aElmenhorst, David$$b8$$ufzj
001037886 7001_ $$0P:(DE-Juel1)131672$$aBauer, Andreas$$b9$$ufzj
001037886 909CO $$ooai:juser.fz-juelich.de:1037886$$pec_fundedresources$$pVDB$$popenaire
001037886 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131691$$aForschungszentrum Jülich$$b0$$kFZJ
001037886 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159581$$aForschungszentrum Jülich$$b2$$kFZJ
001037886 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)151362$$aForschungszentrum Jülich$$b3$$kFZJ
001037886 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133864$$aForschungszentrum Jülich$$b4$$kFZJ
001037886 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b5$$kFZJ
001037886 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b6$$kFZJ
001037886 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131679$$aForschungszentrum Jülich$$b8$$kFZJ
001037886 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131672$$aForschungszentrum Jülich$$b9$$kFZJ
001037886 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001037886 9141_ $$y2024
001037886 920__ $$lyes
001037886 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
001037886 980__ $$aposter
001037886 980__ $$aVDB
001037886 980__ $$aI:(DE-Juel1)INM-2-20090406
001037886 980__ $$aUNRESTRICTED